Trade Summary

3 days ago, Murdoch Travis, serving as CEO and President at Braveheart Bio, Inc. (BRVE), purchased 83,333 shares at $18.00 per share, for a total transaction value of $1,499,994.00. Following this transaction, Murdoch Travis now holds 2,940,670 shares of BRVE.

This purchase represents a 2.92% increase in Murdoch Travis's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, August 7, 2026 and publicly disclosed via SEC Form 4 filing on Friday, August 7, 2026 at 4:30 PM ET, meaning the disclosure happened on the same day as the trade.

Braveheart Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.